Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2003020251 - PROCEDE POUR AMELIORER LA FONCTION ENDOTHELIALE CHEZ LES ETRES HUMAINS

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

CLAIMS

1. A method for enhancing the endothelial function in humans or for treatment or prevention of diseases or disorders of endothelial origin and due to insufficient endothelial function, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

2. A method for the treatment or prevention of
- atherosclerotic vascular diseases,
- vascular spasm associated with angina pectoris,
- micro- or macrovascular complications of diabetes,
- any disease or disorder where a deficit in the formation of nitric oxide for the vascular endothelium appears evident, or
- premature ejaculation and impotence,
comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

3. A method for enhancing growth of blood vessels, particularly in order to increase neovascularization in Angina pectoris and to alleviate said disease, comprising administering to the person an NPY receptor active agent, wherein said receptor is present in the endothelial tissue.

4. The method according to any of the claims 1 to 3 wherein said agent is an NPY receptor agonist.

5. The method according to claim 4 wherein said receptor is the Y2 receptor.

6. The method according to claim 5 wherein i) said agent also is a Yl-receptor agonist or antagonist, or ii) wherein a separate Yl receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.

7. The use of an NPY receptor active agent, said receptor being present in the endothelial tissue of a person, for the manufacture of a pharmaceutical composition for use in a method for enhancing the endothelial function in humans or for treatment or prevention of diseases or disorders of endothelial origin and due to insufficient endothelial function.

8. The use of an NPY receptor active agent, said receptor being present in the endothelial tissue of a person, for the manufacture of a pharmaceutical composition for use in a method for the treatment or prevention of
- atherosclerotic vascular diseases,
- vascular spasm associated with angina pectoris,
- micro- or macrovascular complications of diabetes,
- any disease or disorder where a deficit in the formation of nitric oxide for the vascular endothelium appears evident, or
- premature ejaculation and impotence.

9. The use of an NPY receptor active agent, said receptor being present in the endothelial tissue of a person, for the manufacture of a pharmaceutical composition for use in a method for enhancing growth of blood vessels, particularly in order to increase neovascularization in Angina pectoris and to alleviate said disease.

10. The use according to any of the claims 7 to 9 wherein said agent is an NPY receptor agonist.

11. The use according to claim 10 wherein said receptor is the Y2 receptor.

12. The use according to claim 11 wherein i) said agent also is a Yl -receptor agonist or antagonist, or ii) wherein a separate Yl receptor agonist or antagonist is administered in combination with the Y2 receptor agonist.